Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Freemelt enters strategic agreement with leading global orthopedic implant OEM

Freemelt Holding

Freemelt, has entered into a strategic agreement with another leading global orthopedic implant original equipment manufacturer (OEM) to demonstrate serial production capabilities.

With addition of the previously (Oct 15 2024) announced order from another implant OEM, Freemelt has two global orthopedic implant OEMs among its established customers.

This partnership marks a significant milestone for Freemelt, as the company's industrial machine, eMELT, has been selected by the OEM for a proof-of-concept project to demonstrate serial production capabilities. The eMELT machine will be installed at the OEM's production plant in Q2 2025, marking the beginning of the proof-of-concept phase.

"We are thrilled to have been selected by this esteemed OEM, a true leader in the adoption of additive manufacturing (AM) technology. This partnership is a testament to our team's hard work and dedication to delivering industry-leading productivity and cost efficiency in AM. We look forward to working closely with our new partner to accelerate serial production in additive manufacturing." says Daniel Gidlund, CEO of Freemelt.

The demand for AM-produced implants is projected to grow significantly, from $1.71 billion in 2023 to $6.6 billion by 2032, driven by aging populations and increasing joint replacement needs. Freemelt's eMELT machine is well-positioned to meet this growing demand, offering industry-leading productivity and cost efficiency, particularly for titanium, a material ideally suited for orthopedic implants due to its biocompatibility, strength, and durability.

As part of the partnership, Freemelt will contribute its extensive expertise in E-PBF (Electron Beam Powder Bed Fusion) technology and provide process and application engineering support to the project. This collaboration will enable the OEM to leverage Freemelt's expertise and technology to drive innovation and growth in the orthopedic implants market.

Contacts


For more information, please contact:
Daniel Gidlund, CEO
daniel.gidlund@freemelt.com
070-246 45 01

Certified Advisor
Eminova Fondkomission AB
adviser@eminova.se

About Us


Founded in 2017 by a team of experienced engineers, Freemelt develops advanced 3D printers for metal components and is based in Gothenburg, Sweden. Freemelt primarily serves companies in the defense, energy, and medical technology sectors in Europe and the U.S., helping them innovate and improve production efficiency. Freemelt’s modular printers, designed for industrial applications, support complex geometries and high-performance materials, such as tungsten for defense and energy applications and titanium for medical implants. Backed by strategic investors, Freemelt is well-positioned for continued growth as it advances into the next phase of commercialization. Read more at www.freemelt.com

Attachments


Freemelt enters strategic agreement with leading global orthopedic implant OEM

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.